Understanding Genetic Vaccines and Mechanisms of Action
Genetic vaccines, including mRNA vaccines developed by leading pharmaceutical companies like Pfizer-BioNTech and Moderna, function by introducing genetic material encoding viral antigens, such as the spike protein of SARS-CoV-2, into host cells. This triggers an immune response that primes the body to recognize and combat the virus upon exposure. While these vaccines have demonstrated efficacy in preventing COVID-19 infection, emerging evidence suggests potential risks associated with their use, particularly regarding post-vaccination thrombotic events, cardiovascular complications, and systemic organ-related disorders.
Comment: There don't appear to be any benefits from the Covid vaccines, mRNA or otherwise; quite the contrary: Study finds majority of patients with long COVID were vaccinated
Risks Associated with Blood Transfusions from Genetic Vaccine Recipients
Recent research conducted by institutions such as Asahikawa Medical University, Tokyo Medical University Hospital, MCL Corporation, Kyoto, Okamura Memorial Hospital, Tokyo University of Science, and Kokoro Medical Corporation in Japan has highlighted the risks associated with blood transfusions involving individuals who have received COVID-19 mRNA vaccines. These risks encompass a spectrum of potential complications, including but not limited to:
- Blood Abnormalities
- Immune Dysfunction
- Neurological Complications
Comment: That seems to have been, at least partly, the intention: RNA Vaccines, Obedience and Eugenics
Proposed Measures and Recommendations
In response to these identified risks, the following measures and recommendations are proposed to mitigate potential harm and ensure the safety of blood transfusions involving genetic vaccine recipients:
Comprehensive Testing Protocols
Develop and implement rigorous testing protocols to assess the safety of blood products derived from genetic vaccine recipients. This includes screening for spike proteins, vaccine components, immune markers, and potential neurotoxicity indicators to identify any adverse effects.
Regulatory Guidelines
Establish clear regulatory guidelines governing the collection, processing, storage, and transfusion of blood products from genetic vaccine recipients. These guidelines should outline strict protocols for donor screening, product labeling, and adverse event reporting to enhance safety and accountability.
Long-Term Monitoring and Surveillance
Conduct long-term monitoring and surveillance studies to track the health outcomes and potential complications associated with blood transfusions from genetic vaccine recipients. This includes monitoring for thrombotic events, immune-related disorders, neurological manifestations, and other adverse reactions.
Public Awareness and Education
Increase public awareness and education about the risks and benefits of genetic vaccines, blood transfusions, and immune-related disorders. This includes providing accurate information to healthcare professionals, patients, and the general public to facilitate informed decision-making and healthcare practices.
Legislations
Laws and regulations need to be amended such that all sources of blood for transfusions are labelled as to whether they were from vaccinated or unvaccinated sources and also the recipients should have the rights to reject whatever types they do not feel comfortable with.
Comment: This is a luxury the general public are unlikely to have access to.
Conclusion
The risks associated with blood transfusions from COVID-19 mRNA vaccinated individuals are a significant concern that necessitates proactive measures and comprehensive strategies. By implementing robust testing protocols, regulatory guidelines, long-term monitoring, and public education initiatives, we can mitigate potential harm and ensure the safety and well-being of individuals receiving blood products from genetic vaccine recipients. Collaborative efforts among healthcare institutions, regulatory authorities, researchers, and the public are essential in addressing these challenges and fostering a culture of safety in transfusion medicine amid evolving vaccination strategies and infectious disease landscapes.
The study findings were published on a preprint server and are currently being peer reviewed.
https://www.preprints.org/manuscript/202403.0881/v1
Had a hard time getting past that line. Good luck getting unvaxxed blood if you need it. That would go against what the aim of the whole program is.